ESC Premium Access

Selatogrel, a novel P2Y12 inhibitor for emergency use, achieves rapid, consistent and sustained platelet inhibition following single-dose subcutaneous administration in stable CAD patients

Congress Session

About the speaker

Professor Robert Storey

Department of Cardiovascular Science, University of Sheffield, Sheffield (United Kingdom of Great Britain & Northern Ireland)
17 presentations
1 follower

3 more presentations in this session

State of the Art - Novel targets in anti thrombotic drug development

Speaker: Associate Professor B. Rocca (Rome, IT)


Novel direct thrombin inhibitor achieves superior antithrombotic effect with lower bleeding risk than heparin or bivalirudin

Speaker: Assistant Professor C. Koh (Singapore, SG)


Evaluation of the pharmacodynamics of a ticagrelor reversal agent PB2452

Speaker: Professor L. Jennings (Memphis, US)


Access the full session

New developments in anti thrombotic drug therapy

Speakers: Professor R. Storey, Associate Professor B. Rocca, Assistant Professor C. Koh, Professor L. Jennings

About the event



31 August - 4 September 2019

Sessions Presentations

This platform is supported by

logo Novo Nordisk